Top Markets
#1 Akedo Akedo +59.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.41%
#4 Velvet Velvet +39.92%
#5 Black Phoenix Black Phoenix +34.56%
#6 Ο„emplar Ο„emplar +22.94%
#7 Cap Cap +19.28%
#8 Ribbita by Virtuals Ribbita by Virtuals +17.77%
#9 Cross Cross +15.77%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.57%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Kedudukan dalam Saham #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Harga Saham
$0.02468497
Modal Pasaran
$1.01M
Perubahan (1 hari)
-12.50%
Perubahan (1 tahun)
-87.34%
Negara
AU
Perdagangan Chimeric Therapeutics Limited (CHM)

Kategori

Healthcare
Pendapatan untuk Chimeric Therapeutics Limited (CHM)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Chimeric Therapeutics Limited, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Chimeric Therapeutics Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE